PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer - Pfizer pfizer.com Submitted by pfizercom6279 on December 16, 2023 at 10:07 PM in business No comments 50